Purpose: Correct identification of tumour receptor status is important for treatment decisions in breast cancer. [F]FES PET and [F]FDHT PET allow non-invasive assessment of the oestrogen (ER) and androgen receptor (AR) status of individual lesions within a patient. Despite standardised analysis techniques, interobserver variability can significantly affect the interpretation of PET results and thus clinical applicability. The purpose of this study was to determine visual and quantitative interobserver variability of [F]FES PET and [F]FDHT PET interpretation in patients with metastatic breast cancer.
Methods: In this prospective, two-centre study, patients with ER-positive metastatic breast cancer underwent both [F]FES and [F]FDHT PET/CT. In total, 120 lesions were identified in 10 patients with either conventional imaging (bone scan or lesions > 1 cm on high-resolution CT, n = 69) or only with [F]FES and [F]FDHT PET (n = 51). All lesions were scored visually and quantitatively by two independent observers. A visually PET-positive lesion was defined as uptake above background. For quantification, we used standardised uptake values (SUV): SUV, SUV and SUV.
Results: Visual analysis showed an absolute positive and negative interobserver agreement for [F]FES PET of 84% and 83%, respectively (kappa = 0.67, 95% CI 0.48-0.87), and 49% and 74% for [F]FDHT PET, respectively (kappa = 0.23, 95% CI - 0.04-0.49). Intraclass correlation coefficients (ICC) for quantification of SUV, SUV and SUV were 0.98 (95% CI 0.96-0.98), 0.97 (95% CI 0.96-0.98) and 0.89 (95% CI 0.83-0.92) for [F]FES, and 0.78 (95% CI 0.66-0.85), 0.76 (95% CI 0.63-0.84) and 0.75 (95% CI 0.62-0.84) for [F]FDHT, respectively.
Conclusion: Visual and quantitative evaluation of [F]FES PET showed high interobserver agreement. These results support the use of [F]FES PET in clinical practice. In contrast, visual agreement for [F]FDHT PET was relatively low due to low tumour-background ratios, but quantitative agreement was good. This underscores the relevance of quantitative analysis of [F]FDHT PET in breast cancer.
Trial Registration: ClinicalTrials.gov, NCT01988324. Registered 20 November 2013, https://clinicaltrials.gov/ct2/show/NCT01988324?term=FDHT+PET&draw=1&rank=2.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167394 | PMC |
| http://dx.doi.org/10.1186/s13550-020-00627-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review.
Diagnostics (Basel)
August 2023
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
The aim of this systematic review is to provide a comprehensive overview of the role of fluoro-5α-dihydrotestosterone ([F]-FDHT) for the in vivo imaging of androgen receptors (AR) through positron emission tomography (PET) in metastatic breast (mBC) and metastatic castration-resistant prostate cancer (mCRPC). Relevant studies published from 2013 up to May 2023 were selected by searching Scopus, PubMed and Web of Science. The selected imaging studies were analyzed using a modified version of the critical Appraisal Skills Programme (CASP).
View Article and Find Full Text PDFReport on the PET/CT Image-Based Radiation Dosimetry of [F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer.
J Nucl Med Technol
September 2023
Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts.
In a prospective clinical trial, [F]fluoro-5α-dihydrotestosterone ([F]FDHT), the radiolabeled analog of the androgen dihydrotestosterone, was used as a PET/CT imaging agent for in vivo assessment of metastatic androgen receptor-positive breast cancer in postmenopausal women. To our knowledge, this article presents the first report of PET/CT image-based radiation dosimetry of [F]FDHT in women. [F]FDHT PET/CT imaging was performed on a cohort of 11 women at baseline before the start of therapy and at 2 additional time points during selective androgen receptor modulator (SARM) therapy for androgen receptor-positive breast cancer.
View Article and Find Full Text PDFAndrogen Receptor Imaging in the Management of Hormone-Dependent Cancers with Emphasis on Prostate Cancer.
Int J Mol Sci
May 2023
Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic.
Prostate cancer is dependent on the action of steroid hormones on the receptors. Endocrine therapy inhibits hormone production or blocks the receptors, thus providing clinical benefit to many, but not all, oncological patients. It is difficult to predict which patient will benefit from endocrine therapy and which will not.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore the potential of PET imaging as a substitute for traditional tumor sample analysis in newly diagnosed prostate cancer patients, using two different PET tracers: [Ga]PSMA and 16β-[F]FDHT.
- Results indicated a strong correlation between the SUV/SUV ratio of 16β-[F]FDHT and androgen receptor (AR) expression in tumor tissue, while the correlation for [Ga]PSMA and prostate-specific membrane antigen (PSMA) was less significant, though still positive.
- The findings showed that [Ga]PSMA had a higher tumor detection rate (90%) compared to [F]FDHT (40%), suggesting that while both tracers have potential, [Ga]
Imaging Androgen Receptors in Breast Cancer with F-Fluoro-5α-Dihydrotestosterone PET: A Pilot Study.
J Nucl Med
January 2022
Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.
Most breast cancers express androgen receptors (ARs). This prospective imaging substudy explored imaging of ARs with F-fluoro-5α-dihydrotestosterone (F-FDHT) PET in patients with metastatic breast cancer (MBC) receiving selective AR modulation (SARM) therapy (GTx-024). Eleven postmenopausal women with estrogen receptor-positive MBC underwent F-FDHT PET/CT at baseline and at 6 and 12 wk after starting SARM therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!